Older Adults with COPD More Likely to Receive Potentially Risky Cannabinoid Prescriptions, Study Finds

A large Canadian population study flags higher-frequency, higher-dose off-label cannabinoid use in a vulnerable respiratory population, but its descriptive design cannot assess whether these prescribing patterns actually led to adverse clinical outcomes.

Why This Matters

Chronic obstructive pulmonary disease affects millions of older adults worldwide, and the expanding off-label use of synthetic cannabinoids for pain, insomnia, and refractory dyspnea raises important questions about safety in this physiologically vulnerable population. Cannabinoids carry theoretical respiratory risks, including sedation-related hypoventilation and suppression of respiratory drive, yet population-level data on who is actually receiving these prescriptions has been lacking. Understanding prescribing patterns in at-risk groups is an essential precondition for the prospective outcomes research needed to determine whether real harm is occurring.

Clinical Summary

Older adults with COPD often live with significant symptom burdens, including chronic pain, insomnia, anxiety, and refractory breathlessness, all of which may prompt clinicians to consider synthetic oral cannabinoids such as nabilone and dronabinol. A retrospective population-based cohort study by Vozoris and colleagues, published in Clinical and Investigative Medicine, used linked Ontario health administrative databases to examine a decade of dispensing data (2005 to 2015) among adults aged 66 and older. The authors employed a validated COPD identification algorithm with 95.4% specificity and defined incident use through a one-year washout period, providing a reasonably rigorous pharmacoepidemiologic framework for identifying new off-label users.

The study found that incident off-label synthetic oral cannabinoid use was approximately twice as common among older adults with COPD (0.6%) compared to those without COPD (0.3%), a statistically significant difference (p less than 0.001). COPD patients who used these drugs also tended toward longer treatment durations and higher doses than their non-COPD counterparts. However, absolute rates of use remained low in both groups, and the study did not measure any clinical outcomes such as respiratory exacerbations, hospitalizations, or deaths. The authors explicitly note that the findings are hypothesis-generating and that prospective outcomes research is needed before any conclusions about actual harm or changes to prescribing practice can be recommended.

Dr. Caplan’s Take

This study does something important that often gets overlooked: it maps the terrain before anyone tries to build on it. Before we can ask whether synthetic cannabinoids harm COPD patients, we need to know whether COPD patients are actually getting these drugs, and in what patterns. Now we know they are receiving them at higher rates, for longer, and at higher doses than the general older population. That is a plausible safety signal, and it deserves serious follow-up. But it is not evidence of harm. The patients I see who ask about cannabinoids for COPD-related symptoms deserve an honest answer, and that answer right now is that we do not have outcomes data to guide us.

In practice, when older patients with COPD present with refractory symptoms that might prompt cannabinoid consideration, I prioritize evidence-based interventions first: optimized bronchodilator therapy, pulmonary rehabilitation, structured symptom management for pain and insomnia. If a synthetic cannabinoid is already prescribed, I review the indication carefully, assess for respiratory sedation risk, and ensure the dose and duration are justified. I do not reflexively discontinue, but I also do not initiate without a clear rationale and close monitoring. The evidence simply is not mature enough to do otherwise.

Clinical Perspective

This study sits early in the research arc for cannabinoid safety in COPD. It confirms what many clinicians have suspected: that synthetic oral cannabinoids are being used off-label in older respiratory patients, likely for symptom management of conditions like chronic pain and insomnia that are highly prevalent in COPD. What it does not do is establish whether these prescribing patterns cause harm. The absence of outcomes data means that the “potentially concerning” label the authors apply to higher-dose, longer-duration use in COPD is a reasonable hypothesis, not a confirmed risk. Clinicians should not interpret this study as evidence against cannabinoid use in COPD; rather, they should interpret it as evidence that the question has not yet been answered.

From a pharmacological standpoint, nabilone and dronabinol both carry sedative properties that could, in theory, suppress respiratory drive or exacerbate hypercapnia in patients with advanced COPD and already compromised ventilatory mechanics. Drug interactions with commonly co-prescribed medications in COPD patients, including opioids, benzodiazepines, and certain antidepressants, could compound these risks. Clinicians managing older COPD patients who are receiving synthetic cannabinoids should conduct a thorough medication reconciliation that explicitly accounts for cumulative sedation burden and should document the clinical rationale for continued use at each review.

Study at a Glance

Study Type

Retrospective population-based cohort study

Population

Ontario adults aged 66 and older; 172,282 with COPD and 1,068,256 without COPD

Intervention

Incident dispensing of nabilone or dronabinol (synthetic oral cannabinoids)

Comparator

Older adults without COPD during the same period

Primary Outcomes

Incidence, dose, duration, and predictors of off-label synthetic oral cannabinoid use

Sample Size

1,240,538 total

Journal

Clinical and Investigative Medicine

Year

2015

DOI or PMID

PMID: Not specified in source data

Funding Source

Not specified in source data

What Kind of Evidence Is This

This is a retrospective population-based cohort study using linked health administrative databases. It sits in the observational tier of the evidence hierarchy, well below randomized controlled trials and systematic reviews. Its descriptive design can characterize prescribing patterns and identify statistical associations between patient characteristics and drug use, but it cannot establish causation, confirm clinical intent behind prescriptions, or determine whether the observed prescribing patterns resulted in adverse respiratory outcomes.

How This Fits With the Broader Literature

The broader literature on cannabinoid safety in respiratory disease remains sparse and largely preclinical or theoretical. While some case reports and small series have raised concerns about respiratory depression with cannabinoid use in patients with compromised pulmonary function, no large prospective study has systematically evaluated respiratory outcomes in COPD patients prescribed synthetic cannabinoids. This Ontario study fills a foundational gap by establishing that a differential prescribing pattern exists, confirming that the safety question is not hypothetical but grounded in real-world utilization data.

The study complements earlier pharmacoepidemiologic work examining opioid and benzodiazepine prescribing in COPD, where similar patterns of higher use in respiratory populations eventually prompted prospective safety evaluations. It effectively places synthetic cannabinoids on the same research trajectory, arguing that utilization data should precede and inform the design of outcomes studies.

Common Misreadings

The most likely overinterpretation is concluding that synthetic cannabinoids are dangerous for COPD patients. This study does not measure harm. It documents that COPD patients receive these drugs more often and at higher doses, but the leap from “potentially concerning prescribing pattern” to “demonstrated respiratory risk” is one the data cannot support. Equally problematic would be dismissing the findings because absolute rates were low; the higher relative rate and the pattern of intensified use in a vulnerable population constitute a legitimate pharmacovigilance signal that warrants further investigation, even if the absolute numbers are small.

Bottom Line

This large Canadian cohort study establishes that older adults with COPD receive off-label synthetic oral cannabinoids more frequently, at higher doses, and for longer durations than their non-COPD peers. It does not establish that this pattern causes harm. The study generates a credible pharmacovigilance signal that should prompt prospective outcomes research. Until such research is available, clinicians should document their rationale for cannabinoid prescribing in COPD patients and monitor carefully for sedation and respiratory effects.

References

1. Vozoris NT, et al. Incident off-label synthetic oral cannabinoid use among older adults with COPD: a population-based cohort study. Clinical and Investigative Medicine. 2015.